AS

Amit Sharad Kele

Active Director Director DIN 09540073
DIN 09540073 First appointment Mar 2022 Primary industry Healthcare
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2022
Shareholding value β€’β€’β€’β€’ Premium profile

About Amit Sharad Kele

Data last updated:

Amit Sharad Kele is a Director at Samprakruti Hospicare Private Limited (since 2022). The company operates in Healthcare.

DIN 09540073
Primary Designation Director
Industry Healthcare
First Appointment 18 Mar 2022
Oldest Company Age 4 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director18 Mar 20222022Active

Directorship timeline

Open interactive timeline →
Samprakruti Hospicare Private Limited
Premium access

Shareholding and investment profile for Amit Sharad Kele

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Amit Sharad Kele

Amit Sharad Kele currently holds 1 directorship: Samprakruti Hospicare Private Limited (Director, since 18 Mar 2022).

Amit Sharad Kele was first appointed on 18 Mar 2022 as Director at Samprakruti Hospicare Private Limited.

The current boards of Amit Sharad Kele's companies include Jaywant Kedarnath Kothawade (Samprakruti Hospicare Private Limited), Jitesh Madhukar Patil (Samprakruti Hospicare Private Limited), Manita Kothawade (Samprakruti Hospicare Private Limited), Shailesh Bhikan Mahajan (Samprakruti Hospicare Private Limited), Vishal Ashok Hiray (Samprakruti Hospicare Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available